KalVista Pharmaceuticals Inc
0.0 %
-42.74 %
Yet to be announced
Company Overview
KalVista Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The company's lead program is KVD900, an oral plasma kallikrein inhibitor in development for the treatment of hereditary angioedema (HAE).
The company is currently in the pre-revenue research and development phase, focusing on advancing its clinical pipeline and has not yet commercialized any products.
Revenue Sources
KalVista Pharmaceuticals is a pre-revenue company focused on developing treatments for hereditary angioedema. The company has not generated any revenue in the past four quarters as it is still in the clinical development phase. Their primary focus is on developing legitimate medical treatments, which is a halal business activity.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
As a pre-revenue company still in R&D phase, we skip the interest ratio calculations. The financial data shows zero interest income and zero interest expense for the past four quarters. The company's expenses are primarily related to research and development activities.
Operational Ethics
Based on review of the company's operations and public disclosures, there is no evidence of material ongoing associations with entities involved in human rights violations. The company's operations are primarily based in the United States and United Kingdom, with no identified presence or partnerships in Israel or direct ties to the Chinese Communist Party.
Login to join the discussion